Experimentica Oy Announces Appointment of New Managing Director
Experimentica Oy announces the appointment of a new Managing Director. The current CEO will transition to the role of Executive Chairman.
Learn more
Meet Experimentica at the 5th Gene Therapy for Ophthalmic Disorders Summit in Boston
Experimentica attends the 5th Gene Therapy for Ophthalmic Disorders Summit in Boston, Sept. 10-12, 2024.
Learn more
ARVO 2024 presentation: Dose-Dependent Retinal Damage in a LED White Light Model
The current study aimed to design and test a white light induction system using energy efficient LEDs capable of producing photoreceptor degeneration in a dose-dependent manner.
Learn more
Experimentica attends ARVO 2024 (booth #1440)
Experimentica is pleased to announce its participation in the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2024.
Learn more
Experimentica Ltd. renews French CIR accreditation
France's Crédit d'Impôt Recherche incentive can cover up to 30% of R&D expenses incurred by innovative French pharma and biotech companies working with Experimentica.
Learn more
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
In an article published in JoVE our R&D Team describes detailed protocols for the OIR model induction and its readouts in both mice and rats.
Learn more
